Three gene editing startups, Intellia Therapeutics, Caribou Biosciences and CRISPR Therapeutics, have signed an agreement surrounding the intellectual property of the hotly contested revolutionary gene editing technology CRISPR/Cas9. The companies have entered into the deal with Charpentier of the Helmholtz Centre and the University of California. The deal encourages all parties to enforce and protect CRISPR's IP and clarifies the worldwide IP position of its signatories. Many will see this move as a hedge against any potential fallout from the current patent lawsuit between MIT/Harvard and UC Berkeley for the IP rights to CRISPR/Cas9, which may total many billions of dollars.
Three gene editing startups, Intellia Therapeutics, Caribou Biosciences and CRISPR Therapeutics, have signed an agreement surrounding the intellectual property of the hotly contested revolutionary gene editing technology CRISPR/Cas9. The companies have entered into the deal with Emmanuelle Charpentier of the Helmholtz Centre and the University of California. The deal encourages all parties to enforce and protect CRISPR's IP and clarifies the worldwide IP position of its signatories. Many will see this move as a hedge against any potential fallout from the current patent lawsuit between MIT/Harvard and UC Berkeley for the IP rights to CRISPR/Cas9, which may total many billions of dollars.